Cannabinoid Hyperemesis Syndrome Is Increasingly Common but Often Missed
As cannabis legalization expands, CHS prevalence is rising, yet many healthcare providers still miss the diagnosis; treatment involves benzodiazepines for acute attacks and amitriptyline (50-200 mg/day) for long-term management.
Quick Facts
What This Study Found
CHS typically presents with episodic vomiting from chronic daily cannabis use over months to years, with nausea and abdominal pain improved by hot showers. Symptoms resolve with cannabis cessation over 6-12 months. Acute treatment uses parenteral benzodiazepines. Long-term prevention uses amitriptyline 50-200 mg/day, which can be slowly tapered after remission.
Key Numbers
Amitriptyline dose: 50-200 mg/day for prevention. Symptom resolution: 6-12 months after cannabis cessation. In the US, 52.5 million people aged 12+ used cannabis in 2021.
How They Did This
Narrative review of current literature on CHS prevalence, diagnosis, and management in the context of expanding cannabis legalization.
Why This Research Matters
CHS remains unrecognized by many providers, leading to repeated ER visits, unnecessary testing, and delayed treatment. As cannabis becomes more widely available, providers need clear diagnostic and treatment frameworks.
The Bigger Picture
CHS represents one of the most concrete health consequences of heavy cannabis use. Its increasing prevalence provides a measurable signal of how expanded access translates to specific health system burden.
What This Study Doesn't Tell Us
Narrative review without systematic search methodology. Treatment recommendations are based on limited evidence and clinical experience. The pathophysiology of CHS remains incompletely understood.
Questions This Raises
- ?Why do only some chronic cannabis users develop CHS?
- ?Is the rising prevalence purely due to increased use, or also improved recognition?
- ?Are there genetic or other factors that predict CHS susceptibility?
Trust & Context
- Key Stat:
- Amitriptyline 50-200 mg/day recommended for long-term CHS prevention
- Evidence Grade:
- Narrative review synthesizing clinical evidence and expert recommendations.
- Study Age:
- 2024 review
- Original Title:
- Cannabinoid hyperemesis syndrome: prevalence and management in an era of cannabis legalization.
- Published In:
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 72(2), 171-177 (2024)
- Authors:
- Stubbs, Justin Joe, McCallum, Richard(2)
- Database ID:
- RTHC-05738
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
How is cannabinoid hyperemesis syndrome treated?
Acute episodes are treated with intravenous benzodiazepines. Long-term prevention uses amitriptyline at 50-200 mg/day. The definitive treatment is cannabis cessation, with symptoms typically resolving over 6-12 months.
Is CHS becoming more common?
Yes. As more states legalize cannabis, CHS prevalence has increased. Many healthcare providers still do not recognize the condition, leading to delayed diagnosis.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBT-cannabis-recovery
- THC-potency-increase-over-time
- cannabis-harm-reduction-opioids-alcohol-replacement
- cannabis-legalization-effects-health-data
- cannabis-relapse-cycle-pattern
- cannabis-tolerance-break-guide
- cold-turkey-vs-taper-quit-weed
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-cut-back-on-weed-moderation
- how-to-quit-weed
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- microdosing-cannabis-benefits
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- safer-cannabis-use-guidelines
- should-i-quit-weed
- sober-music-festival-concert-without-weed
- sober-october-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- tolerance-break-weed
- weed-for-opioid-withdrawal
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
Cite This Study
https://rethinkthc.com/research/RTHC-05738APA
Stubbs, Justin Joe; McCallum, Richard. (2024). Cannabinoid hyperemesis syndrome: prevalence and management in an era of cannabis legalization.. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 72(2), 171-177. https://doi.org/10.1177/10815589231217495
MLA
Stubbs, Justin Joe, et al. "Cannabinoid hyperemesis syndrome: prevalence and management in an era of cannabis legalization.." Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2024. https://doi.org/10.1177/10815589231217495
RethinkTHC
RethinkTHC Research Database. "Cannabinoid hyperemesis syndrome: prevalence and management ..." RTHC-05738. Retrieved from https://rethinkthc.com/research/stubbs-2024-cannabinoid-hyperemesis-syndrome-prevalence
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.